Use of liposomal doxorubicin for adjuvant chemotherapy of breast cancer in clinical practice

Zhao, Ming; Ding, Xiaohu; Shen, Jian-yu; Zhang, Xiping; Ding, Xiaowen; Xu, Bin

doi:10.1631/jzus.b1600303

Cited by 63 publications

(53 citation statements)

References 53 publications

(52 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Two liposomal formulations have been approved for use with certain defined clinical indications. One liposomal DOX (Caelyx ® Janssen Pharmaceutica NV, Beerse (Belgium) in Europe and Doxil ® Janssen Products LP, Horsham (England) in the USA) has polyethylene glycol (PEG) embedded in the lipid layer; other formulations of DOX (Myocet ® ) GP‐Pharm, Barcelona (Spain) adopt uncoated liposomes …”

Section: Strategies For Preventionmentioning

confidence: 99%

Update on pathophysiology and preventive strategies of anthracycline‐induced cardiotoxicity

Corremans

Adão

Keulenaer

et al. 2018

Clin Exp Pharma Physio

View full text Add to dashboard Cite

Summary Anthracycline chemotherapy has a prominent role in treating many forms of cancer. Unfortunately, cardiotoxic side effects represent a serious limitation to their use, with doxorubicin being the leading drug of the group. Indeed, anthracycline‐induced cardiomyopathy is an important public health concern because it may not be detected for many years and remains a lifelong threat. Even after decades of investigation, neither the exact mode of action of anthracyclines nor the pathways leading to their side effect are fully understood. It is increasingly important to establish collaboration between oncologists and cardiologists to improve the management of cancer patient receiving anthracyclines. This article reviews the clinical course, pathogenesis, cardiac monitoring and new concepts in diagnosing and preventing anthracycline‐induced cardiotoxicity.

show abstract

Section: Strategies For Preventionmentioning

confidence: 99%

Update on pathophysiology and preventive strategies of anthracycline‐induced cardiotoxicity

Corremans

Adão

Keulenaer

et al. 2018

Clin Exp Pharma Physio

View full text Add to dashboard Cite

show abstract

“…Typically, taxanes and anthracyclines are included in the chemotherapy treatment protocol. The most widely used drug for patients with breast cancer metastases is doxorubicin (sold under the trade names Adriamycin and Adriblastina, among others) .…”

Section: Introductionmentioning

confidence: 99%

Fullerene as a doxorubicin nanotransporter for targeted breast cancer therapy: Capillary electrophoresis analysis

2018

View full text Add to dashboard Cite

The clinical use of doxorubicin (DOX) is limited by dose-related cardiomyopathy, which becomes more prevalent with increasing cumulative doses of the drug. Complexes of fullerene with DOX were designed and studied using biophysical methods. The ability of DOX to release from fullerene at different pHs was analyzed. It has been shown that the size of the fullerene-DOX complexes was ∼280 nm. The zeta potential for fullerene was -30 mV, for DOX -8 mV, and for fullerene-DOX conjugates -24 mV. Drug release was studied by CE with LIF detection. When fullerene-DOX conjugates were separated in a pH 7.5 buffer, 43% of all DOX signals were derived from free DOX, with the signal increasing as pH decreased. At pH 5.25, all DOX had been released and 100% of the signal was derived from free DOX. The release of DOX from complexes with fullerene at lower pH can be used in targeted antineoplastic therapy, resulting in lower toxicity for less acidic non-target tissue.

show abstract

“…We demonstrated that the mag.SLPs were capable of effective killing of human tumor cells, including their drug-resistant sublines, even without a conjugated anticancer drug. The anticancer effect of the mag.SLPs was comparable to that of doxorubicin (Dox), a cornerstone and gold standard in the anticancer chemotherapy (Lippens et al, 1998;Minotti et al, 2004;Zhao et al, 2017).…”

Section: Introductionmentioning

confidence: 94%

Magnetic Temperature-Sensitive Solid-Lipid Particles for Targeting and Killing Tumor Cells

et al. 2020

View full text Add to dashboard Cite

Magnetic and temperature-sensitive solid lipid particles (mag. SLPs) were prepared in the presence of oleic acid-coated iron oxide (IO-OA) nanoparticles with 1-tetradecanol and poly(ethylene oxide)-block-poly(ε-caprolactone) as lipid and stabilizing surfactant-like agents, respectively. The particles, typically ∼850 nm in hydrodynamic size, showed heat dissipation under the applied alternating magnetic field. Cytotoxic activity of the mag.SLPs, non-magnetic SLPs, and iron oxide nanoparticles was compared concerning the mammalian cancer cell lines and their drug-resistant counterparts using trypan blue exclusion test and MTT assay. The mag.SLPs exhibited dose-dependent cytotoxicity against human leukemia cell lines growing in suspension (Jurkat and HL-60/wt), as well as the doxorubicin (Dox)-and vincristine-resistant HL-60 sublines. The mag.SLPs showed higher cytotoxicity toward drug-resistant sublines as compared to Dox. The human glioblastoma cell line U251 growing in a monolayer culture was also sensitive to mag.SLPs cytotoxicity. Staining of U251 cells with the fluorescent dyes Hoechst 33342 and propidium iodide (PI) revealed that mag.SLPs treatment resulted in an increased number of cells with condensed chromatin and/or fragmented nuclei as well as with blebbing of the plasma membranes. While the Hoechst 33342 staining of cell suggested the pro-apoptotic activity of the particles, the PI staining indicated the pro-necrotic changes in the target cells. These conclusions were confirmed by Western blot analysis of apoptosis-related proteins, study of DNA fragmentation (DNA laddering due to the inter-nucleosomal cleavage and DNA comets due to single strand breaks), as well as by FACS analysis of the patterns of cell cycle distribution (pre-G1 phase) and Annexin V/PI staining of the treated Jurkat cells. The induction of apoptosis or necrosis by the particles used to treat Jurkat cells depended on the dose of the particles. Production of the reactive oxygen species (ROS) was proposed as a potential mechanism of mag.SLPs-induced cytotoxicity. Accordingly, hydrogen peroxide and superoxide radical Ś więtek et al.Magnetic Solid-Lipid Particles levels in mag.SLPs-treated Jurkat leukemic cells were increased by ∼20-40 and ∼70%, respectively. In contrast, the non-magnetic SLPs and neat iron oxides did not influence ROS levels significantly. Thus, the developed mag.SLPs can be used for effective killing of human tumor cells, including drug-resistant ones.

show abstract

Use of liposomal doxorubicin for adjuvant chemotherapy of breast cancer in clinical practice

Cited by 63 publications

References 53 publications

Update on pathophysiology and preventive strategies of anthracycline‐induced cardiotoxicity

Update on pathophysiology and preventive strategies of anthracycline‐induced cardiotoxicity

Fullerene as a doxorubicin nanotransporter for targeted breast cancer therapy: Capillary electrophoresis analysis

Magnetic Temperature-Sensitive Solid-Lipid Particles for Targeting and Killing Tumor Cells

Contact Info

Product

Resources

About